Clinical Trials

23 enrolled

Head & Neck

Thyroid Neoplasms

NCT07388875 2026-02-05

SKB264-ANLO

Small Cell Lung Carcinoma

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07358520 2026-01-22

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

40 enrolled

Proteinuria

NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

28 enrolled

Lung Neoplasms

NCT07294261 2025-12-19

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

46 enrolled

Sarcoma

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

59 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07128693 2025-08-19

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT07075250 2025-07-20

RIFOC003

Gynecologic

Platinum-resistant Ovarian Cancer (PROC)

NCT06977828 2025-06-29

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07022301 2025-06-15

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

25 enrolled

Small Cell Lung Cancer Extensive Stage

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Head & Neck

Thyroid Neoplasms

NCT06978153 2025-05-18

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

66 enrolled

Limited Stage Small Cell Lung Cancer

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT06931145 2025-04-23

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

50 enrolled

Small Cell Lung Carcinoma

NCT06851169 2025-02-28

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

58 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06761417 2025-01-08

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

49 enrolled

Other solid neoplasm

Solid Tumors

NCT06699498 2024-11-21

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

Phase 1 Not yet recruiting

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06699576 2024-11-21

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

448 enrolled

Sarcoma

Sarcoma, Osteosarcoma

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Phase 2/3 Not yet recruiting

206 enrolled

Biliary Tract Neoplasms

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

104 enrolled

Phase NA Not yet recruiting

Pancreatic Neoplasms

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

Breast

Breast Neoplasms

NCT06483672 2024-07-03

LungBrain001

27 enrolled

CNSThoracic

Adenocarcinoma of Lung, Brain Neoplasms

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

178 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

60 enrolled

Tumor-Agnostic

Neoplasms

NCT06426797 2024-05-23

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

25 enrolled

Esophageal Squamous Cell Carcinoma

NCT06327698 2024-03-25

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Dermatologic

Melanoma

NCT06221462 2024-01-25

PRIORITY

Carcinoma, Non-Small-Cell Lung

NCT06222944 2024-01-25

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

90 enrolled

Stomach Neoplasms

NCT06182761 2023-12-27

WUKONG-9

45 enrolled

Phase 3 Not yet recruiting

NSCLC

NCT06048315 2023-09-21

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

52 enrolled

Lung Neoplasms

NCT05996484 2023-08-21

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

25 enrolled

Esophageal Neoplasms

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled